Sunovion

Sunovion Pharmaceuticals

Sunovion is a subsidiary of Sumitomo Pharma.

Sunovion Pharmaceuticals Inc. is a global biopharmaceutical company focused on the innovative application of science and medicine to help people with serious medical conditions. Sunovion is a subsidiary of Sumitomo Pharma, a leading Japanese pharmaceutical company.

History

Sunovion was established in 2010 following the acquisition of Sepracor Inc. by Dainippon Sumitomo Pharma Co., Ltd. The company has its headquarters in Marlborough, Massachusetts, and operates in various countries around the world.

Products

Sunovion develops and markets a range of pharmaceutical products primarily in the areas of psychiatry, neurology, and respiratory diseases. Some of its well-known products include:

• Latuda (lurasidone HCl) - an atypical antipsychotic used for the treatment of schizophrenia and bipolar disorder.
• Brovana (arformoterol tartrate) - a long-acting beta-agonist (LABA) used for the maintenance treatment of chronic obstructive pulmonary disease (COPD).
• Aptiom (eslicarbazepine acetate) - an anticonvulsant used for the treatment of epilepsy.

Research and Development

Sunovion is committed to advancing research in the fields of psychiatry, neurology, and respiratory diseases. The company invests significantly in clinical trials and collaborates with academic institutions and other pharmaceutical companies to develop new therapies.

Corporate Social Responsibility

Sunovion engages in various corporate social responsibility (CSR) initiatives, focusing on improving patient access to medications, supporting community health programs, and promoting environmental sustainability.

Related pages

• Sumitomo Pharma
• Pharmaceutical industry
• Biopharmaceutical
• Clinical trial